Precigen, Inc. (NASDAQ:PGEN) Shares Bought by AQR Capital Management LLC

AQR Capital Management LLC grew its holdings in shares of Precigen, Inc. (NASDAQ:PGEN) by 56.7% during the second quarter, according to its most recent Form 13F filing with the SEC. The firm owned 50,002 shares of the biotechnology company’s stock after purchasing an additional 18,097 shares during the period. AQR Capital Management LLC’s holdings in Precigen were worth $79,000 as of its most recent SEC filing.

A number of other large investors have also modified their holdings of the company. Vanguard Group Inc. increased its holdings in shares of Precigen by 0.3% in the 1st quarter. Vanguard Group Inc. now owns 6,768,234 shares of the biotechnology company’s stock worth $9,814,000 after acquiring an additional 19,875 shares during the period. Iridian Asset Management LLC CT increased its holdings in shares of Precigen by 4.3% in the 1st quarter. Iridian Asset Management LLC CT now owns 2,091,274 shares of the biotechnology company’s stock worth $3,032,000 after acquiring an additional 86,340 shares during the period. Renaissance Technologies LLC grew its position in Precigen by 12.4% in the 2nd quarter. Renaissance Technologies LLC now owns 1,182,690 shares of the biotechnology company’s stock valued at $1,869,000 after buying an additional 130,500 shares in the last quarter. ClariVest Asset Management LLC grew its position in Precigen by 2.9% in the 2nd quarter. ClariVest Asset Management LLC now owns 492,152 shares of the biotechnology company’s stock valued at $778,000 after buying an additional 13,752 shares in the last quarter. Finally, Bank of New York Mellon Corp grew its position in Precigen by 4.8% in the 2nd quarter. Bank of New York Mellon Corp now owns 421,788 shares of the biotechnology company’s stock valued at $666,000 after buying an additional 19,301 shares in the last quarter. Institutional investors and hedge funds own 33.51% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on PGEN. HC Wainwright reduced their price objective on shares of Precigen from $6.00 to $4.00 and set a “buy” rating for the company in a research report on Thursday, August 15th. JMP Securities reduced their price target on shares of Precigen from $14.00 to $7.00 and set a “market outperform” rating for the company in a research report on Thursday, August 15th. Finally, StockNews.com raised shares of Precigen to a “sell” rating in a research report on Thursday, August 1st. Two investment analysts have rated the stock with a sell rating and four have assigned a buy rating to the stock. Based on data from MarketBeat, Precigen has a consensus rating of “Hold” and a consensus price target of $7.00.

Insiders Place Their Bets

In related news, SVP Jeffrey Thomas Perez acquired 58,823 shares of the business’s stock in a transaction on Friday, August 9th. The stock was bought at an average cost of $0.85 per share, with a total value of $49,999.55. Following the completion of the acquisition, the senior vice president now owns 743,097 shares in the company, valued at $631,632.45. The trade was a 0.00 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Corporate insiders own 44.90% of the company’s stock.

Precigen Stock Up 4.2 %

Shares of PGEN stock opened at $0.95 on Friday. Precigen, Inc. has a 12 month low of $0.82 and a 12 month high of $1.93. The business’s 50 day moving average is $1.00 and its two-hundred day moving average is $1.31. The company has a market cap of $240.91 million, a PE ratio of -1.76 and a beta of 1.66.

Precigen (NASDAQ:PGEN) last announced its quarterly earnings data on Wednesday, August 14th. The biotechnology company reported ($0.10) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.09) by ($0.01). The company had revenue of $0.72 million during the quarter, compared to analyst estimates of $1.28 million. Precigen had a negative return on equity of 90.99% and a negative net margin of 3,084.55%. As a group, equities analysts expect that Precigen, Inc. will post -0.44 EPS for the current fiscal year.

About Precigen

Precigen, Inc operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar.